Search Results

Small Molecules in Oncology from Emerging Companies: 2021’s IPOs Pt. III

This article is Part 3 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 2 provided an overview of 2021 IPOs by therapeutic area. This short article takes a…

Part II: High Level Overview of 2021 IPOs by Therapy Area

This article is Part 2 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1(link to article) provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class.  This short article takes a deeper look into the 2021 IPOs by technology and…

Drug Discovery IPOs in 2022Q1

We did a comprehensive review of industry news in 2022Q1 (there was.. a lot of stuff to cover). This article highlights companies focused on drug discovery that IPO’d in the first quarter. The Drug Discovery IPO Market Slowdown As everyone knows, biotech’s been in a bear market since Feb. 2021 (with the entire $XBI index…

Scientific Highlights from 2020’s Drug Discovery Biotech IPOs

Recently, our team at Drug Hunter compiled the lead programs and mechanisms of small molecule and large molecule biotechs that IPO’d in 2020. We asked featured reviewers from our community what stood out to them about the science of this group of companies, and here are some highlights that emerged from the discussion. Any thoughts and comments shared are personal opinions only and…

2020 Biotech IPOs – Small Molecule R&D Companies

Looking at the pipelines of recent biotech IPOs is a great way to get a snapshot of new technologies and approaches to drug discovery or to see what’s coming in smaller indications. Complementing our recent highlight of large molecule-focused companies, below is a summary of 2020’s class of biotech IPOs focused on small molecule drug…